[go: up one dir, main page]

EP1326605A4 - USE OF INHIBITORS OF THE BINDING OF LEUKOTRIEN B4 TO LEUKOTRIEN B4 RECEPTOR TO INHIBIT PROLIFERATION AND INDUCTION OF APOPTOSE IN CANCER CELLS - Google Patents

USE OF INHIBITORS OF THE BINDING OF LEUKOTRIEN B4 TO LEUKOTRIEN B4 RECEPTOR TO INHIBIT PROLIFERATION AND INDUCTION OF APOPTOSE IN CANCER CELLS

Info

Publication number
EP1326605A4
EP1326605A4 EP01935770A EP01935770A EP1326605A4 EP 1326605 A4 EP1326605 A4 EP 1326605A4 EP 01935770 A EP01935770 A EP 01935770A EP 01935770 A EP01935770 A EP 01935770A EP 1326605 A4 EP1326605 A4 EP 1326605A4
Authority
EP
European Patent Office
Prior art keywords
leukotrien
apoptose
inhibitors
receptor
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01935770A
Other languages
German (de)
French (fr)
Other versions
EP1326605A1 (en
Inventor
Thomas E Adrian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creighton University
Original Assignee
Creighton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creighton University filed Critical Creighton University
Publication of EP1326605A1 publication Critical patent/EP1326605A1/en
Publication of EP1326605A4 publication Critical patent/EP1326605A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01935770A 2000-05-09 2001-05-08 USE OF INHIBITORS OF THE BINDING OF LEUKOTRIEN B4 TO LEUKOTRIEN B4 RECEPTOR TO INHIBIT PROLIFERATION AND INDUCTION OF APOPTOSE IN CANCER CELLS Withdrawn EP1326605A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21934400P 2000-05-09 2000-05-09
US219344P 2000-05-09
PCT/US2001/040697 WO2001085166A1 (en) 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
EP1326605A1 EP1326605A1 (en) 2003-07-16
EP1326605A4 true EP1326605A4 (en) 2004-03-17

Family

ID=22818912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01935770A Withdrawn EP1326605A4 (en) 2000-05-09 2001-05-08 USE OF INHIBITORS OF THE BINDING OF LEUKOTRIEN B4 TO LEUKOTRIEN B4 RECEPTOR TO INHIBIT PROLIFERATION AND INDUCTION OF APOPTOSE IN CANCER CELLS

Country Status (11)

Country Link
EP (1) EP1326605A4 (en)
JP (1) JP2003532675A (en)
KR (1) KR20030019372A (en)
CN (1) CN1237968C (en)
AU (1) AU2001261832A1 (en)
BR (1) BR0110473A (en)
CA (1) CA2408622A1 (en)
MX (1) MXPA02010974A (en)
NO (1) NO20025343L (en)
NZ (1) NZ522387A (en)
WO (1) WO2001085166A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
EP2034022A1 (en) 2007-09-10 2009-03-11 Universite Libre De Bruxelles Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
EP2802557B1 (en) 2012-01-10 2016-04-06 Eli Lilly and Company Leukotriene b4 antagonist compound
JP5858391B2 (en) 2013-04-22 2016-02-10 株式会社栃木臨床病理研究所 Antitumor agent
RS57642B1 (en) 2013-12-20 2018-11-30 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
WO1996006604A2 (en) * 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034135A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034137A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9904672A2 (en) * 1997-03-21 2000-05-28 Eli Lilly And Co. Leukotriene antagonists for oral squamous cell carcinoma

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
WO1996006604A2 (en) * 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034135A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034137A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO0185166A1 *
STEELE V E ET AL: "LIPOXYGENASE INHIBITORS AS POTENTIAL CANCER CHEMOPREVENTIVES", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH,, US, vol. 8, no. 5, May 1999 (1999-05-01), pages 467 - 483, XP000984604, ISSN: 1055-9965 *

Also Published As

Publication number Publication date
CN1237968C (en) 2006-01-25
NO20025343L (en) 2003-01-09
AU2001261832A1 (en) 2001-11-20
KR20030019372A (en) 2003-03-06
BR0110473A (en) 2003-04-01
MXPA02010974A (en) 2004-09-06
NZ522387A (en) 2003-09-26
CA2408622A1 (en) 2001-11-15
JP2003532675A (en) 2003-11-05
CN1429111A (en) 2003-07-09
WO2001085166A1 (en) 2001-11-15
EP1326605A1 (en) 2003-07-16
NO20025343D0 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
DE60017894D1 (en) DIAMINOTHIAZOLE AND ITS USE IN THE INHIBITION OF PROTEIN KINASES
ATE401909T1 (en) USE OF SOLUBLE CTLA4 MUTANTS TO TREAT RHEUMATOID ARTHRITIS
ATE329987T1 (en) USE OF FISCHER-TROPSCH/CRACK FRACTION MIXTURES TO ACHIEVE LOW EMISSIONS
ATE245032T1 (en) USE OF NEUROTOXINS IN MEDICATIONS TO TREAT THYROID DISORDERS
NO20034169D0 (en) MCH antagonists and their use in the treatment of obesity
DE60208661D1 (en) DIAMINOTHIAZOLE AND THEIR USE AS CYCLINE-DEPENDENT KINASE INHIBITORS
ATE418336T1 (en) USE OF I KAPPA B-KINASE INHIBITORS IN PAIN THERAPY
ATE307597T1 (en) USE OF PEG-IFN-ALPHA AND RIBAVIRIN TO TREAT CHRONIC HEPATITIS C
DE60028552D1 (en) Use of dipeptidyl peptidase IV inhibitors to improve fertility
DE60032226D1 (en) METHOD FOR THE INDUCTION OF CANCER CELL AND TUMOR REGRESSION
NO20013288D0 (en) Determination of water saturation and sand fraction
DE60221804D1 (en) BENZIMIDAZOLE DERIVATIVES FOR IGE MODULATION AND CELL PROLIFERATION INHIBITION
DE10196065T1 (en) Use of AIN as a copper passivation layer and heat conductor
ATE338557T1 (en) USE OF COX2 INHIBITORS TO TREAT SCHIZOPHRENIA AND THE TIC
DE60110232D1 (en) NEW USE OF LIPASE INHIBITORS
ATE329906T1 (en) SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THEIR USE AS NHE INHIBITORS
DE60100392D1 (en) Modified polypropylene resin composition and use in laminates
NO20013577L (en) Tumor necrosis factor antagonists and their use in endometriosis
DE50008527D1 (en) USE OF CGRP ANTAGONISTS AND CGRP RELEASE INHIBITORS FOR COMBATING MENOPAUSAL HOT WALLS
DE69907802D1 (en) Thermal plasters and their use
EE200100514A (en) Inhibitors of LFA-1 binding to ICAMs and their use
EP1326605A4 (en) USE OF INHIBITORS OF THE BINDING OF LEUKOTRIEN B4 TO LEUKOTRIEN B4 RECEPTOR TO INHIBIT PROLIFERATION AND INDUCTION OF APOPTOSE IN CANCER CELLS
DE60102122D1 (en) Composition of poly-1-butene resin and its use
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
DK1165136T3 (en) Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steriodal aldosterone antagonist to treat cardiovascular disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021205

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040130

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/00 B

Ipc: 7A 61K 31/445 B

Ipc: 7A 61K 31/44 B

Ipc: 7A 61K 31/352 B

Ipc: 7A 61K 31/194 B

Ipc: 7A 61K 31/41 A

17Q First examination report despatched

Effective date: 20041007

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061031

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1057471

Country of ref document: HK